Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial von Geurts, V.C.M., Voorwerk, L., Balduzzi, S., Salgado, R., Van de Vijver, K., van Dongen, M.G.J., Kemper, I., Mandjes, I.A.M., Heuver, M., Sparreboom, W., Haanen, J.B.A.G., Sonke, G.S., Horlings, H.M., Kok, M.

Volltext

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response von Lips, E. H., Mulder, L., de Ronde, J. J., Mandjes, I. A. M., Koolen, B. B., Wessels, L. F. A., Rodenhuis, S., Wesseling, J.

Volltext

90TiP Monalizumab and trastuzumab in metastatic HER2-positive breast cancer: MIMOSA-trial von Geurts, V.C.M., Voorwerk, L., Sikorska, K., Van Dongen, M.G., Kemper, I., Mandjes, I.A.M., Haanen, J.B.A.G., Sonke, G.S., Kok, M.

Volltext

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004... von van Rossum, A.G.J., Kok, M., van Werkhoven, E., Opdam, M., Mandjes, I.A.M., van Leeuwen – Stok, A.E., van Tinteren, H., Imholz, A.L.T., Portielje, J.E.A., Bos, M.M.E.M., van Bochove, A., Wesseling, J., Rutgers, E.J., Linn, S.C., Oosterkamp, H.M.

Volltext

Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics von Lips, E. H., Mulder, L., de Ronde, J. J., Mandjes, I. A. M., Vincent, A., Vrancken Peeters, M. T. F. D., Nederlof, P. M., Wesseling, J., Rodenhuis, S.

Volltext

135TiP GELATO-trial: Assessing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer von Voorwerk, L., Horlings, H.M., Dongen, M.V., Kemper, I., Mandjes, I.A.M., Boers, J., Schröder, C.P., Tjan-Heijnen, V., Jager, A., Schumacher, T.N., Blank, C.U., De Visser, K.E., Linn, S., Kok, M.

Volltext

A simple system for grading the response of breast cancer to neoadjuvant chemotherapy von Rodenhuis, S., Mandjes, I.A.M., Wesseling, J., van de Vijver, M.J., Peeters, M.-J. T. D. F. Vrancken, Sonke, G.S., Linn, S.C.

Volltext

163MO Single-cell T cell dynamics induced by neoadjuvant nivolumab +/- ipilimumab in early triple negative breast cancer with tumor-infiltrating lymphocytes (BELLINI trial) von Isaeva, O.I., Nederlof, I., de Graaf, M., Boeckx, B., Traets, J., Mandjes, I.A.M., Van De Vijver, K., Chelushkin, M., Drukker, C., Dongen, M.V., Sonke, G.S., Linn, S.C., Blank, C.U., de Visser, K.E., Salgado, R.F., Wessels, L.F.A., Schumacher, T.N., Horlings, H.M., Lambrechts, D., Kok, M.

Volltext

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response von Lips, E.H, Mulder, L, de Ronde, J.J, Mandjes, I.A.M, Koolen, B.B, Wessels, L.F.A, Rodenhuis, S, Wesseling, J

Volltext

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial von Voorwerk, L., Isaeva, O.I., Horlings, H.M., Balduzzi, S., Chelushkin, M., Bakker, N.A.M., Champanhet, E., Garner, H., Sikorska, K., Loo, C.E., Kemper, I., Mandjes, I.A.M., Maaker, M. de, Geel, J.J.L. van, Boers, J., Boer, M. de, Salgado, R., Dongen, M.G.J. van, Sonke, G.S., Visser, K.E. de, Schumacher, T.N., Blank, C.U., Wessels, L.F.A., Jager, A., Tjan-Heijnen, V.C.G., Schroder, C., Linn, S.C., Kok, M.

Volltext bestellen

Differential survival and therapy benefit of patients with breast cancer are characterized by distinct epithelial and immune cell microenvironments von Kester, L., Seinstra, D., Rossum, A.G.J. van, Vennin, C., Hoogstraat, M., Velden, D. van der, Opdam, M., Werkhoven, E. van, Hahn, K., Nederlof, I., Lips, E.H., Mandjes, I.A.M., Leeuwen-Stok, A.E. van, Canisius, S., Tinteren, H. van, Imholz, A.L.T., Portielje, J.E.A., Bos, M.E.M.M., Bakker, S.D., Rutgers, E.J., Horlings, H.M., Wesseling, J., Voest, E.E., Wessels, L.F.A., Kok, M., Oosterkamp, H.M., Oudenaarden, A. van, Linn, S.C., Rheenen, J. van

Volltext bestellen

Carboplatin-cyclophosphamide or paclitaxel without or with bevacizumab as first-line treatment for metastatic triple-negative breast cancer (BOOG 2013-01) von Rossum, A.G.J. van, Mandjes, I.A.M., Werkhoven, E. van, Tinteren, H. van, Leeuwen-Stok, A.E. van, Nederlof, P., Portielje, J.E.A., Alphen, R.J. van, Platte, E., Broek, D. van den, Huitema, A., Kok, M., Linn, S.C., Oosterkamp, H.M.

Volltext bestellen

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004... von Rossum, A.G.J. van, Kok, M., Werkhoven, E. van, Opdam, M., Mandjes, I.A.M., Leeuwen-Stok, A.E. van, Tinteren, H. van, Imholz, A.L.T., Portielje, J.E.A., Bos, M.M.E.M., Bochove, A. van, Wesseling, J., Rutgers, E.J., Linn, S.C., Oosterkamp, H.M.

Volltext bestellen